In an ongoing multicenter study called DESTINY-Lung01, the effectiveness of T-DXd in treating patients with non-squamous NSCLC overexpressing HER2 or containing a HER2-activating mutation is being tested [107]. Here, ERBB2 is linked to non-small cell lung carcinoma.